Compared with placebo, ivermectin does not shorten symptom duration or prevent hospitalisation in patients with mild or moderate COVID-19, according to new research findings.

ACTIV-6 is an ongoing clinical trial designed to evaluate the effectiveness of repurposed drugs that are already approved for the treatment of other diseases but not...